TCTMD
VerifiedOnline/Digital
TMD is the most comprehensive on-line resource in interventional cardiology and provides indepth coverage of the percutaneous treatment of cardiovascular disease. Since its launch at TCT 2000, TCTMD has provided clinicians and industry professionals myriad ways to keep up-to-date in the ever-evolving field, including news and data from conferences hosted around the world as well as information about the latest devices and drugs used in the daily practice of cardiovascular medicine.
TCTMD is produced and administered by the Cardiovascular Research Foundation (CRF). CRF's mission is to strive to improve the quality of life for patients with cardiovascular disease. The organization's goal is to advance the development and use of safe and effective minimally invasive cardiovascular treatments. For more information, visit our Web site at http://www.crf.org. Source
Actions
Media Outlet details
| Scope | National, Trade/B2B |
|---|---|
| Language | English, Spanish |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesTRIC-I-HF Scores Big Clinical Wins for TTVR in High-risk Patients
MUNICH, Germany—Transcatheter tricuspid valve repair (TTVR) added to medical therapy decreases the likelihood of death and hospitalization for heart failure (HF) compared with medical therapy alone, while also improving quality of life (QoL) in patients with severe tricuspid regurgitation, according to results of the TRIC-I-HF trial.
AIR-STEMI: Angiography-Derived FFR Informs Complete PCI in STEMI
MUNICH, Germany—For STEMI patients with multivessel disease, the use of angiography-based functional assessment to guide complete revascularization improves outcomes compared with conventional angiography alone, according to results from the AIR-STEMI trial. Better clarity on which nonculprit lesions merited treatment reduced the combined risk of death from any cause, MI, cerebrovascular accident (stroke or transient ischemic attack), or ischemia-driven revascularization by 38% in the study.
Prasugrel by Default in ACS Patients Post-PCI Lowers Bleeding With No Ischemic Penalty
News Conference News ESC 2026 SWITCH-SWEDEHEART’s unique design randomized healthcare regions but wasn’t a head-to-head comparison with ticagrelor. MUNICH, Germany—When prasugrel is considered the default antiplatelet choice for patients with acute coronary syndromes who undergo PCI, fewer major bleeding events occur than if the default had been ticagrelor, according to results from the registry-based SWITCH-SWEDEHEART study.
STAREE: Statins Cut MACE Risk by 30% in Older Adults With No CVD History
MUNICH, Germany—People over age 70 with no history of cardiovascular disease see dramatic reductions in major adverse cardiovascular events when newly prescribed statin therapy for primary prevention, according to results of the STAREE trial. Compared with those given placebo, patients taking 40 mg of atorvastatin once daily had a 30% lower incidence of CV death, nonfatal MI, stroke, or coronary revascularization (6.0% vs 8.3%; P < 0.001) over the 6-year study period.
AMUNDSEN: Early PCSK9 Inhibition Provides Big Drop in LDL After Acute MI
Among patients with acute MI, initiating PCSK9 inhibitor therapy in the cath lab before PCI markedly improves control of LDL cholesterol over the first year compared with standard care alone, according to the results of the AMUNDSEN trial.
Beyond the Data: SWITCH-SWEDEHEART
Mamas Mamas, Elmir Omerovic, and Jurriën ten Berg discuss the impact of policies switching from ticagrelor to prasugrel as the default antiplatelet choice for ACS patients undergoing PCI.
The POET II RCT Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis
The POET II RCT Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis Presenter: Henning Bundgaard Up Next Presenter: Henning Bundgaard August 28, 2026
Scarring Doesn’t Tip the Scale Towards ICDs in Cardiomyopathy With LVEF of 36-50%
MUNICH, Germany—Patients with an LVEF in the range of 36% to 50% and myocardial scar on cardiac magnetic resonance (CMR) imaging do not experience an overall reduction in sudden cardiac death (SCD) and hemodynamically significant ventricular arrhythmias when treated with a primary-prevention implantable cardioverter-defibrillator (ICD) versus an implantable loop recorder (ILR), according to data from the CMR GUIDE trial. However, there were some signs of benefit apart from that primary endpoint.
Aficamten Wins in Nonobstructive Hypertrophic Cardiomyopathy: ACACIA-HCM
News Conference News ESC 2026 The findings open the door to regulatory approval for this patient group without other treatment options. Among patients with nonobstructive hypertrophic cardiomyopathy (HCM), the selective cardiac myosin inhibitor aficamten (Myqorzo; Cytokinetics) increases exercise capacity and improves symptoms compared with placebo at 36 weeks, according to results from the ACACIA-HCM trial.
Tirzepatide Nabs Indication for MACE Reduction in Type 2 Diabetes
The drug becomes the first dual GLP-1/GIP receptor agonist available for lowering CV risk in this population. The US Food and Drug Administration has granted an expanded indication to tirzepatide (Mounjaro) for reducing major adverse cardiovascular events in adults with type 2 diabetes at elevated risk, drugmaker Lilly announced Friday.